Today: 7 February 2026
Subscribe
Browse Category

Biotech Industry News 10 January 2026 - 6 February 2026

Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny

Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny

Adaptive Biotechnologies shares fell 5.2% to $15.61 Friday after Q4 revenue jumped 51% to $71.7 million and the company forecast 2026 MRD revenue of $255–$265 million. CEO Chad Robins disclosed selling 124,998 shares on Feb. 2. BTIG raised its price target to $22. The stock traded between $17.69 and $15.08 during the session.
6 February 2026
·····
Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens

Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens

Atossa Therapeutics will enact a 1-for-15 reverse stock split Monday, after shares closed Friday at $0.565, down 6%. The move aims to lift the price above Nasdaq’s $1 minimum ahead of a Feb. 17 compliance deadline. Shares will trade under a new CUSIP and fractional shares will be paid out in cash. Options contracts will be adjusted to reflect the split.
2 February 2026
····
Thermo Fisher (TMO) stock drops after 2026 profit outlook misses on research funding cuts

Thermo Fisher (TMO) stock drops after 2026 profit outlook misses on research funding cuts

Thermo Fisher shares fell 2.6% to $592.08 after the company forecast 2026 adjusted profit below Wall Street estimates, citing continued weakness in U.S. academic and government funding. The firm projected 2026 adjusted EPS of $24.22–$24.80 and revenue of $46.3–$47.2 billion. Fourth-quarter revenue rose 7% to $12.21 billion. Investors are watching the timing of the Clario acquisition, expected to close by mid-2026.
29 January 2026
·····
Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

New York, January 21, 2026, 05:22 EST — Premarket Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase. (Public) Novavax’s deal is significant as the company looks to pivot its platform toward steadier revenue sources amid a drop in pandemic vaccine sales. Investors are increasingly focused on partnerships that bring upfront payments plus ongoing royalties, moving away from relying solely on seasonal demand surges. Pfizer is zeroing in on Matrix‑M, an adjuvant that amplifies the immune
21 January 2026
······
Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug

Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug

ZURICH, Jan 17, 2026, 18:33 CET — Market closed. Novartis AG (NVS) shares ended Friday on a positive note after the Swiss pharma giant revealed that U.S. regulators awarded fast-track designation to its ianalumab programme. This move brings immunology back into focus ahead of the company’s earnings report. (MarketScreener) The FDA’s Breakthrough Therapy designation is designed to accelerate the development and review of drugs targeting serious conditions, provided early clinical data points to a significant improvement over current treatments. (U.S. Food and Drug Administration) The timing is key since Novartis will report its quarterly and full-year results on Feb. 4.
17 January 2026
····
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

New York, January 17, 2026, 07:32 EST — Market closed. Shares of Pfizer Inc (PFE) closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight. The next real hurdle for the stock arrives Tuesday. U.S. markets shut Monday for Martin Luther King Jr. Day, tightening the news flow and often making the session after the holiday a bit jittery. (NYSE) Pfizer CEO Albert Bourla expressed he was “seriously frustrated” following U.S. Health Secretary Robert F. Kennedy Jr.’s decision to roll back
17 January 2026
·····
Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

New York, Jan 14, 2026, 14:09 EST — Regular session Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end. This matters since Nuvalent remains a clinical-stage company. Investors want a clearer timeline for its first possible U.S. product launch and some indication it won’t need to raise capital again anytime soon. Nuvalent’s update sets a firm deadline for the next major catalyst: the U.S. Food and Drug Administration’s decision timeline on its first potential approval, a move
14 January 2026
····
NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

New York, Jan 14, 2026, 08:52 EST — Premarket NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide every 11 minutes.” (GlobeNewswire) The headline carries weight since NRx is a small, clinical-stage biotech. Its valuation hinges on regulatory progress, and Fast Track status can speed up the usual back-and-forth that drags out drug approvals. This comes as investors
14 January 2026
·····
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13

NEW YORK, Jan 13, 2026, 14:32 (EST) — Regular session Shares of Ligand Pharmaceuticals Incorporated dropped 10.6% to $184.80 in Tuesday afternoon trading. The decline followed an announcement from royalty partner Travere Therapeutics that U.S. regulators extended the review period for its Filspari application, pushing the decision date to April 13. Travere said the FDA classified its latest submission as a “major amendment” but didn’t request additional safety or manufacturing data. LGND shares opened at $196.96 and fluctuated between $175.89 and $206.78. (Business Wire) The timing cuts deep, given this was a straightforward, immediate trigger for Ligand’s royalty setup. Traders
13 January 2026
·····
Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

New York, Jan 12, 2026, 15:14 (EST) — Regular session Mesoblast Ltd’s shares on the U.S. market dropped roughly 11% Monday, sliding to $18.64 in afternoon trading after hitting $20.14 earlier. The Australian biotech’s stock has seen sharp swings since it started highlighting early commercial progress for its main cell therapy. The pullback is significant since Mesoblast has moved beyond being just a clinical-stage story, now driven by product sales and cash flow. Investors have been parsing every update on Ryoncil sales and financing as a gauge of the company’s actual runway. A director’s share purchase in Australia failed to
12 January 2026
····
Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

Liquidia stock jumps after $148 mln Yutrepia sales update — what to watch next week

New York, Jan 10, 2026, 19:48 EST — Market closed Shares of Liquidia Corp surged 12.9% on Friday, closing at $35.86 following a preliminary sales update on its pulmonary hypertension drug YUTREPIA. The company also reported positive cash flow in Q4. During the session, the stock hit a high of $38.07 and was trading about 1.5% higher in after-hours, per Yahoo Finance data. (Yahoo Finance) For Liquidia, the question remains: can YUTREPIA sustain its early momentum, or will script rates flatten as the launch matures? This week, that question gains weight as the company’s update arrives just before the J.P.
11 January 2026
·····
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

New York, Jan 10, 2026, 14:37 EST — Market closed Merck & Co (MRK) closed Friday 0.4% lower at $110.53 following reports that the pharmaceutical giant is negotiating to acquire cancer drug developer Revolution Medicines in a deal valued between $28 billion and $32 billion. (Reuters) Timing is crucial. As Merck faces patent losses on its blockbuster cancer drug Keytruda later this decade, it’s searching for new growth drivers. A deal of this magnitude would sharply indicate just how aggressive the company intends to get. The week also arrives with investors gearing up for policy turbulence tied to vaccines and
10 January 2026
·····
1 2 3 4

Stock Market Today

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

7 February 2026
Confluent shares closed at $30.57 Friday, 43 cents below IBM’s $31-per-share cash offer, ahead of key events next week. The company will report earnings Feb. 11 without a call or outlook, and shareholders vote on the merger Feb. 12. Confluent disclosed 17 demand letters and two lawsuits over proxy disclosures but denies wrongdoing. The IBM deal values Confluent at $11 billion.
BitMine Immersion (BMNR) stock whipsaws with ether — what to watch before Monday

BitMine Immersion (BMNR) stock whipsaws with ether — what to watch before Monday

7 February 2026
BitMine Immersion Technologies shares rose 16.8% to $20.32 Friday after a 14.3% drop Thursday, tracking sharp swings in ether and bitcoin. Trading volume hit 54 million shares. The company held over 4.2 million ether and 193 bitcoin as of Feb. 1, with nearly 2.9 million ether staked, according to an SEC filing. Crypto price moves over the weekend are expected to drive Monday’s open.
Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

Verizon stock price snaps 7-day run as consumer chief exit sharpens focus on turnaround

7 February 2026
Verizon shares fell 1.7% to $46.31 Friday, ending a seven-session rally and closing about 2.7% below Thursday’s one-year high. The dip follows news that consumer chief Sowmyanarayan Sampath will step down, with Alfonso Villanueva named interim head. Verizon has climbed 16% since January 29 amid strong subscriber growth and a $25 billion buyback plan.
Go toTop